Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Revolution Medicines (RVMD) Current Assets (2019 - 2025)

Revolution Medicines (RVMD) has 7 years of Current Assets data on record, last reported at $2.1 billion in Q4 2025.

  • For Q4 2025, Current Assets fell 10.85% year-over-year to $2.1 billion; the TTM value through Dec 2025 reached $2.1 billion, down 10.85%, while the annual FY2025 figure was $2.1 billion, 10.85% down from the prior year.
  • Current Assets reached $2.1 billion in Q4 2025 per RVMD's latest filing, up from $2.0 billion in the prior quarter.
  • Across five years, Current Assets topped out at $2.3 billion in Q4 2024 and bottomed at $483.0 million in Q2 2022.
  • Average Current Assets over 5 years is $1.3 billion, with a median of $922.4 million recorded in 2023.
  • Peak YoY movement for Current Assets: decreased 26.92% in 2022, then skyrocketed 184.66% in 2023.
  • A 5-year view of Current Assets shows it stood at $589.8 million in 2021, then rose by 11.94% to $660.2 million in 2022, then surged by 184.66% to $1.9 billion in 2023, then increased by 23.86% to $2.3 billion in 2024, then decreased by 10.85% to $2.1 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Current Assets were $2.1 billion in Q4 2025, $2.0 billion in Q3 2025, and $2.2 billion in Q2 2025.